Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement

Blood

Volumn 111, Issue 2, 2008, Pages 732-740

  Kimura, Yuko ^a   Miwa, Takashi ^a   Zhou, Lin ^a   Song, Wen Chao ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; LIPOOLIGOSACCHARIDE; PROPERDIN; ZYMOSAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; ERYTHROCYTE; GENE AMPLIFICATION; GENE TARGETING; HEMOLYSIS; INFECTION RISK; KNOCKOUT MOUSE; MENINGOCOCCOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 38349097639     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-05-089821     Document Type: Article

References (34)

1. Walport MJ. Complement: first of two parts. N Engl J Med. 2001;344:1058-1066.
2. Selander B, Martensson U, Weintraub A, et al. Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest. 2006;116:1425-1434.
3. Kim DD, Song WC. Membrane complement regulatory proteins. Clin Immunol. 2005;118:127-136.
4. Schwaeble WJ, Reid KB. Does properdin crosslink the cellular and the humoral immune response? Immunol Today. 1999;20:17-21.
5. Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AC. The properdin system and immunity: I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science. 1954;120:279-285.
6. Pillemer L, Schoenberg MD, Blum L, Wurz L. Properdin system and immunity: II. Interaction of the properdin system with polysaccharides. Science. 1955;122:545-549.
7. Pillemer L, Blum L, Lepow IH, Wurz L, Todd EW. The properdin system and immunity: III. The zymosan assay of properdin. J Exp Med. 1956;103:1-13.
8. Pillemer L, Landy M, Shear MJ. The properdin system and immunity: VII. Alterations in properdin levels and resistance to infection in mice following the administration of tissue polysaccharides. J Exp Med. 1957;106:99-110.
9. Nelson RA Jr. An alternative mechanism for the properdin system. J Exp Med. 1958;108:515-535.
10. Fearon DT, Austen KF. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med. 1975;142:856-863.
11. Hourcade DE. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J Biol Chem. 2006;281:2128-2132.
12. Sun Z, Reid KB, Perkins SJ. The dimeric and trimeric solution structures of the multidomain complement protein properdin by X-ray scattering, analytical ultracentrifugation and constrained modelling. J Mol Biol. 2004;343:1327-1343.
13. Smith CA, Pangburn MK, Vogel CW, Muller-Eberhard HJ. Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement. J Biol Chem. 1984;259:4582-4588.
14. Bathum L, Hansen H, Teisner B, et al. Association between combined properdin and mannose-binding lectin deficiency and infection with Neisseria meningitidis. Mol Immunol. 2006;43:473-479.
15. Späth PJ, Sjoholm AG, Fredrikson GN, et al. Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m (n). Clin Exp Immunol. 1999;118:278-284.
16. Gelfand EW, Rao CP, Minta JO, Ham T, Purkall DB, Ruddy S. Inherited deficiency of properdin and C2 in a patient with recurrent bacteremia. Am J Med. 1987;82:671-675.
17. Linton SM, Morgan BP. Properdin deficiency and meningococcal disease: identifying those most at risk. Clin Exp Immunol. 1999;118:189-191.
18. Rodríguez CI, Buchholz F, Galloway J, et al. High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat Genet. 2000;25:139-140.
19. Miwa T, Zhou L, Hilliard B, Molina H, Song WC. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack. Blood. 2002;99:3707-3716.
20. Molina H, Miwa T, Zhou L, et al. Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor. Blood. 2002;100:4544-4549.
21. Ram S, Cullinane M, Blom AM, et al. C4bp binding to porin mediates stable serum resistance of Neisseria gonorrhoeae. Int Immunopharmacol. 2001;1:423-432.
22. Sogabe H, Nangaku M, Ishibashi Y, et al. Increased susceptibility of decay-accelerating factor deficient mice to antiglomerular basement membrane glomerulonephritis. J Immunol. 2001;167:2791-2797.
23. Sfyroera G, Katragadda M, Morikis D, Isaacs SN, Lambris JD. Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins. J Immunol. 2005;174:2143-2151.
24. Xu Y, Ma M, Ippolito GC, Schroeder HW Jr, Carroll MC, Volanakis JE. Complement activation in factor D-deficient mice. Proc Natl Acad Sci U S A. 2001;98:14577-14582.
25. Kim DD, Miwa T, Song WC. Retrovirus-mediated over-expression of decay-accelerating factor rescues Crry-deficient erythrocytes from acute alternative pathway complement attack. J Immunol. 2006;177:5558-5566.
26. Mastellos D, Prechl J, Laszlo G, et al. Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. Mol Immunol. 2004;40:1213-1221.
27. Alfieri JA, Martin AD, Takeda J, Kondoh G, Myles DG, Primakoff P. Infertility in female mice with an oocyte-specific knockout of GPI-anchored proteins. J Cell Sci. 2003;116:2149-2155.
28. Westberg J, Fredrikson GN, Truedsson L, Sjoholm AG, Uhlen M. Sequence-based analysis of properdin deficiency: identification of point mutations in two phenotypic forms of an X-linked immunodeficiency. Genomics. 1995;29:1-8.
29. Sjöholm AG, Braconier JH, Soderstrom C. Properdin deficiency in a family with fulminant meningococcal infections. Clin Exp Immunol. 1982;50:291-297.
30. van den Bogaard R, Fijen CA, Schipper MG, de Galan L, Kuijper EJ, Mannens MM. Molecular characterisation of 10 Dutch properdin type I deficient families: mutation analysis and X-inactivation studies. Eur J Hum Genet. 2000;8:513-518.
31. Harboe M, Ulvund G, Vien L, Fung M, Mollnes TE. The quantitative role of alternative pathway amplification in classic pathway induced terminal complement activation. Clin Exp Immunol. 2004;138:439-446.
32. Matsumoto M, Fukuda W, Circolo A, et al. Abrogation of the alternative complement pathway by targeted deletion of murine factor B. Proc Natl Acad Sci U S A. 1997;94:8720-8725.
33. Schreiber RD, Medicus RG, Gitze O, Muller-Eberhard HJ. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med. 1975;142:760-772.
34. Ji H, Ohmura K, Mahmood U, et al. Arthritis critically dependent on innate immune system players. Immunity. 2002;16:157-168.